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Using path signatures to predict a diagnosis of Alzheimer’s disease.
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Abstract
The path signature is a means of feature generation that can encode nonlinear interactions in the data as well as
the usual linear features. It can distinguish the ordering of time-sequenced changes: for example whether or not the
hippocampus shrinks fast, then slowly or the converse. It provides interpretable features and its output is a fixed length
vector irrespective of the number of input points so it can encode longitudinal data of varying length and with missing
data points. In this paper we demonstrate the path signature in providing features to distinguish a set of people with
Alzheimer’s disease from a matched set of healthy individuals. The data used are volume measurements of the whole
brain, ventricles and hippocampus from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The path signature
method is shown to be a useful tool for the processing of sequential data which is becoming increasingly available as
monitoring technologies are applied.
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1. Introduction
Alzheimer’s disease (AD) is an irreversible brain disor-
der which progressively affects cognition and behaviour,
and results in an impairment in the ability to perform
daily activities. It is the most common form of dementia
in older people, affecting about 6% of the population aged
over 65, and it increases in incidence with age. The initial
stage of AD is characterised by memory loss, and this is
the usual presenting symptom. Memory loss is one con-
stituent of mild cognitive impairment (MCI), which can be
an early sign of Alzheimer’s disease. MCI is diagnosed by
complaints of subjective memory loss (preferably corrob-
orated by a close associate or partner of the individual),
impairment of memory function, unimpaired general cog-
nition and behaviour but with no evidence of dementia
[1]. MCI does not always progress to dementia or to a
diagnosis of Alzheimer’s disease, but those with amnestic
mild MCI, the type of MCI characterised by memory im-
pairment, are more likely to develop dementia than those
without this diagnosis. In cases where an individual does
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develop Alzheimer’s disease, the phase of MCI ends with
a marked decline in cognitive function, lasting two to five
years, in which semantic memory (the recall of facts and
general knowledge) and implicit memory (the long-term,
nonconscious memory evidenced by priming effects) also
becomes degraded.
2. Predicting Alzheimer’s disease
The disease pathology leads to a progressive, irreversible
loss of brain function which suggests that prospective drug
therapies should be tested for efficacy as early in the pro-
cess as possible. So there has been a demand for predicting
which individuals will develop AD as early as possible in
order to test drug therapies which might inhibit or pre-
vent tissue damage. Input variables for use with learning
methods may be derived from imaging (in particular MRI),
cognitive tests, physical biomarkers such as APOE status
and demographic variables such as age and gender.
Data. There are a number of data repositories which
are used for studies of Alzheimer’s disease. ADNI, the
Alzheimers Disease Neuroimaging Initiative has been used
in many studies[2]. ADNI is comprised of four phases:
ADNI-1 (2004), ADNI-GO (2009), ADNI-2 (2011), and
ADNI-3 (2016). ADNI is led by Principal Investigator
Michael W. Weiner, MD. For up-to-date information see
www.adni-info.org. Another large scale study is AIBL,
The Australian Imaging Biomarkers and Lifestyle flagship
study of ageing which started in 2016[3]. One European
study is AddNeuroMed which is a public/private consor-
tium developed for AD biomarker discovery [4], and it
has been used for an number of comparative studies. Of
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these, ADNI is the longest running and most cited study,
although there are many other data sets and initiatives
integrating together different datasets.
Competitions. Competitions for accurate prediction of di-
agnosis and biomarker measures have allowed comparisons
between learning methods and feature choice. The CAD-
Dementia challenge [5] compares algorithms for multi-
class classification of AD, MCI and controls based on
structural MRI data. The Kaggle Neuroimaging chal-
lenge https://www.kaggle.com/c/mci-prediction [6]
was hosted on the Kaggle machine learning platform
and used ADNI data. The challenge involved a four-
fold classification into AD, MCI, MCI converters to
AD, and controls. The 2017 TADPOLE grand chal-
lenge https://tadpole.grand-challenge.org/ is cur-
rently taking place with evaluation to be completed
by January 2019. The TADPOLE challenge has the
aim of predicting the onset of Alzheimer’s disease us-
ing different modes of measurement, including demo-
graphic, physical and cognitive data. The challenge is
a three-fold diagnosis classification into AD, MCI and
control groups, and the prediction of ADAS-13 score
and normalised brain volume. A preprocessed form of
the ADNI data from the TADPOLE grand challenge
https://tadpole.grand-challenge.org/ was used in
the preparation of this report[7].
Imaging features. Brain imaging methods can be used to
derive features for predicting diagnosis either by analysis
of the whole brain (voxel-based morphometry) or by de-
riving features from specific brain regions that are known
to change during the course of Alzheimer’s disease. Us-
ing ADNI data, Schmitter et al.[8] found that volume-
based morphometry achieved at least as good an accu-
racy as voxel-based morphometry for typical classification
tasks. Sørensen et al. examined the differential diagnosis
of AD andMCI using features derived fromMRI and found
that the most important MRI biomarkers were; hippocam-
pal volume, ventricular volume, hippocampal texture, and
parietal lobe thickness[9]. Using training data from ADNI
and AIBL, they were ranked as first place on the CADDe-
mentia challenge with a multi-class classification accuracy
of 63%. Westman et al.[10] used the ADNI and AddNeu-
roMed data sets to examine 34 regional cortical thickness
measures and 23 volume measures and found in both co-
horts the most important features to be the entorhinal
cortex, hippocampus and amygdala volumes.
It should be noted that there is heterogeneity among
patients diagnosed with Alzheimer’s disease: Poulakis
et al.[11] identified five groups of patients by clustering
AddNeuroMed and ADNI data on cortical and subcortical
volume measures. The groups were labelled as minimal at-
rophy, limbic-predominant, hippocampal-sparing, and two
diffuse atrophy subtypes, and have different demographic,
clinical and cognitive characteristics and different rates of
cognitive decline.
3. Experiment
In this paper, we aim to demonstrate the application
of the path signature by distinguishing Alzheimer’s and
healthy groups using MRI data as input to a classifier.
In doing so we investigate some of the nonlinear interac-
tions between features, that is the relative changes between
brain regions that occur with aging. The novel aspect is
the use of the path signature for generating features for
classification. The path signature was originally intro-
duced by Chen [12] who applied it to piecewise smooth
paths, and it was further developed by Lyons and oth-
ers [13][14][15][16][17]. It is a systematic way of providing
feature sets for multimodal data that can probe the non-
linear interactions in the data as an extension of linear
features. Since all time-dependent interactions between
variables are encoded, it likely to be useful for detect-
ing unforeseen relationships between variables. Combined
with Lasso regularisation, it can detect situations where
the observed data has nonlinear information that signifi-
cantly improves the inference. Second order information
has proved useful in some applications, for example in [18]
where the method was applied to modelling bipolar disor-
der and borderline personality disorder.
Data. We select two sets from the TADPOLE competition
data for the first classification task. A total of 1737 par-
ticipants are first split into those who have a diagnosis of
Alzheimers disease (AD) at some point (n=688), and the
remainder who remain healthy (NL) (n=341). The AD
set is further selected to have the first diagnosis of AD at
36 months from baseline and with at least four measure-
ments of all the variables WholeBrain, Hippocampus and
Ventricles in the 24 months since baseline, with one mea-
surement at the 24 months time point. The participant
must also have a match in the NL set. To qualify to be
a match to an AD participant, an individual must match
their age to within 6 years and have healthy diagnoses for
72 months since the baseline measurement. The match-
ing time series must also have at least four measurement
points up to month 24 including a measurement at month
24 itself. Characteristics of the selected sets are shown in
Table 1, and sample plots of the time series are shown in
Figure 1.
Method. We take each time series from the AD set up
to the last time point before diagnosis and extract a
similar length time series from the counterpart in the
NL set. The experiment is to identify time series as
belonging to either the AD or NL set by using changes
in relative brain volumes and time. For classification
we use binary logistic regression which models the log
probabilities of the outputs as linear functions of the
inputs. The inputs to the classifier are found using
Lasso regularisation which subtracts an L1 penalty from
the negative log-likelihood when fitting the model. The
input to Lasso is a vector formed from the three ROI
variables: WholeBrain, Hippocampus and Ventricles,
and the path signature which is itself derived from these
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Healthy Alzheimer’s
n: 21 21
Age:
min(mean)max
65.1 (74.8) 89.6 64.6 (75.4) 85.9
Gender M/F: 10/11 10/11
Wholebrain: 1.05 (0.11) 1.00 (0.12)
Hippocampus: 7.67 (0.84) 6.14 (1.41)
Ventricles: 25.43 (19.91) 34.34 (21.17)
median(iqr)
APOE 0: 81% 29%
1: 19% 52%
2: 0% 19%
MMSE 25 3
26 2
27 1 4
28 4 5
29 8 4
30 8 3
Table 1: Demographic and time series characteristics, and APOE4
status for matched healthy participants compared with selected par-
ticipants who have a diagnosis of AD. The variables shown are the
sample size n, age, gender, scaled ROI volumes, APOE4 status and
MMSE score at baseline. In the AD set, 18 of the 21 participants
have a diagnosis of MCI at baseline with the remaining 3 having a
healthy diagnosis.
variables and their time points. The path signature
maps the path of the input variables to a series of
real numbers which uniquely characterise that path, S =
{1, S(1), S(2), S(3), S(4), S(1,1), S(1,2), S(2,2), S(3,2), S(4,2) . . . }.
The superscripts are multi-indexes or words whose total
length is in practice limited to degree k. In this applica-
tion we use k = 2, resulting in a signature length of 21
where the first term, which is always 1, is unused in the
feature vector. The next four terms S(1), S(2), S(3), S(4)
represent the increment of each variable, so in the ex-
periment S(1) is the time period. The next term S(1,1)
is equal to 12 (S
(1,1))2. The cross terms S(1,2) and S(2,1)
both represent the area between the actual path and a
stepped path which increments one coordinate to its final
value, then the next coordinate to its final value. The
log signature is an alternative representation that results
from taking the logarithm in the formal power series and
it is a more compact representation of the path than the
signature. An introduction to the path signature which
gives a geometric explanation of terms up to second
degree can be found in [19].
Training is performed on the entire set of 42 time
series using 10-fold cross-validation to find the graph of
deviance against the Lasso coefficient λ which determines
the strength of regularisation. As the Lasso coefficient
increases, most of the variable coefficients shrink to zero,
leaving a set of variables which act as predictors.
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Figure 1: Sample plots by time (months) of scaled brain volumes for
8 patients, with the top four healthy and the bottom four those with
Alzheimer’s disease. In each graph: Whole brain (blue), Hippocam-
pus (red), Entorhinus (yellow). Diagnosis points are diamonds:
Healthy (green), MCI (yellow), Alzheimer’s disease (red).
4. Results
Training curves for the signature and log signature fea-
tures are shown in Figures 2 and 3. As lambda is in-
creased (from right to left in the figures), the variable co-
efficients shrink and the deviance changes. Table 2 shows
those features that are selected at the point of minimum
deviance plus one standard deviation. Using the log sig-
nature, Lasso selects the baseline (initial) volume of the
ventricles and the change in volume of the hippocampus
and ventricles. Table 1 shows different ventricles sizes for
the two sets, so it is not surprising that this variable was
selected. The selection of hippocampus and volume in-
crements might also be expected from inspection of the
sample graphs in 1. Using the signature, Lasso selects
some interaction terms. The feature (t,t) represents the
square of half the time increment: although the time se-
ries are all nominally of 24 months duration there are mi-
nor differences in the precise date when the MRI image
was taken. The remaining three features are interactions
between variables (w,h), (w,v) and (h,t).
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Signature Log signature
Ventricles baseline Ventricles baseline
(t,t) Hippocampus increment
(t,v) Ventricles increment
(w,h)
(w,v)
(h,t)
Table 2: The set of variables selected by Lasso for the signature
feature set shown in the left hand column, and the log signature
feature set shown in the right hand column. The pairs (t, t) etc. are
nonlinear interactions between variables, with (t, t) = 0.5 ∗ incr(t)2
and for example (t, v) representing the area between the variables
Time and Ventricles.
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Figure 2: Signature training curves using baseline variable values and
the path signature as features. Top: Lasso parameter λ optimisation
using 10-fold cross validation. The green circle and dashed line locate
the Lambda with minimum cross-validation error. The blue circle
and dashed line locate the point with minimum cross-validation error
plus one standard deviation. Bottom: Coefficient shrinkage as λ is
increased.
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Figure 3: Log signature training curves using baseline variable values
and the log path signature as features. Top: Lasso parameter λ
optimisation using 10-fold cross validation. The green circle and
dashed line locate the Lambda with minimum cross-validation error.
The blue circle and dashed line locate the point with minimum cross-
validation error plus one standard deviation. Bottom: Coefficient
shrinkage as λ is increased.
5. Conclusion
The path signature has been used to encode the changes
in time of brain ROI volumes for both healthy individ-
uals and those with Alzheimer’s disease. We cannot at
this stage draw strong conclusions from the selected set
of variables beyond noting that they correspond to known
Alzheimer’s disease pathology, such as the changes in hip-
pocampus and ventricles volume. These processes also oc-
cur in normal aging, though to a lesser extent. The identifi-
cation of interaction terms formed of pairs of ROI variables
is interesting and deserves further exploration. The sig-
nature method generates interpretable nonlinear features
and handles missing and irregular sequential data. While
nonlinear classifiers (neural nets, random forests) can be
accurate, their function can be difficult to interpret. By
encoding nonlinearity into the features, we can use classi-
fiers that give more interpretable results. Sequential data
is becoming increasingly available as monitoring technol-
ogy is applied, and the path signature method is a useful
tool in the processing of this data.
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